Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Bioengineered drug candidate can counter S. aureus infection in early tests

Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

24 Apr 2023

Antibody combination strongly protects high-risk people with early COVID-19 symptoms, trial shows

A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

20 Apr 2023

The economic burden of RSV infections in low and middle-income countries

Researchers discuss the cost-of-illness associated with RSV infections among children in low and middle-income countries.

6 Apr 2023

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

mAb therapy reduces risk of hospitalization and death against Alpha, Delta, and Omicron variants

Researchers assess the efficacy of monoclonal antibodies in treating COVID-19 caused by different viral variants.

6 Apr 2023

Omicron BA.5 variant demonstrates increased neuroinvasiveness and pathogenicity in mice

Researchers assessed the extent of SARS-CoV-2 Omicron VOC BA.5 sub-VOC infection-associated brain infection and death.

5 Apr 2023

Probiotic E. coli secretes proteins of therapeutic value into its surroundings

Humans are colonized with thousands of bacterial strains. Researchers are now focused on genetically modifying such bacteria to enhance their intrinsic therapeutic properties.

31 Mar 2023

Lab-made antibodies may be able to cure people infected with yellow fever

New research from Oregon Health & Science University and collaborators indicates lab-made antibodies may be able to cure people infected with yellow fever, a virus for which there is no treatment.

29 Mar 2023

New combination therapy shows promising results in some patients with advanced head and neck cancer

A new combination drug treatment showed promising results in patients with pan-refractory, recurrent/metastatic head and neck cancer, according to a study published today in the Journal of Clinical Oncology.

28 Mar 2023

New study suggests broad neutralizing antibody could provide three years of COVID protection

In a recent article published in the journal Science Translational Medicine, researchers showed that a novel, lab-engineered monoclonal antibody (mAb), adintrevimab conferred up to 50% protection against symptomatic coronavirus disease 2019 (COVID-19). Furthermore, it demonstrated this exceptional efficacy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–naïve individuals even at titers as low as 1:30.

27 Mar 2023

Disruption of the FcRn–IgG interaction may make AAV-based gene therapies effective

The use of a monoclonal antibody that reduced circulating IgG levels, led to a decrease in preexisting neutralizing antibodies (NAbs) to adeno-associated virus (AAV).

22 Mar 2023

H5N1 avian influenza found in stranded harbor porpoise

In a recent study published in the United States (U.S.) Centers for Disease Control and Prevention (CDC) journal Emerging Infectious Diseases, researchers from Sweden described the detection of the hemagglutinin type 5 and neuraminidase type 1 (H5N1) avian influenza virus in a stranded harbor porpoise, indicating a potential spillover of this highly pathogenic avian influenza virus into cetacean species.

20 Mar 2023

Does vitamin D play an anti-viral role against SARS-CoV-2?

Researchers screened various compounds for anti-viral properties against SARS-CoV-2.

17 Mar 2023

Monoclonal antibody-based blocking ELISA for SARS-CoV-2 detection in animals

In a recent study posted to the bioRxiv* preprint server, researchers in the United States described a blocking enzyme-linked immunosorbent assay (ELISA) to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure in animals.

16 Mar 2023

How to assess clinical response in multiple myeloma

In this interview, Cerba Research explains how its teams were able to assess clinical response in multiple myeloma (MM) patients that were receiving monoclonal antibodies treatment,

From Cerba Research 16 Mar 2023

Study suggests mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19

Researchers investigated whether mRNA technology-based COVID-19 vaccines promote the development of autoantibodies.

14 Mar 2023

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Researchers from The University of Texas MD Anderson Cancer Center have developed fully human bispecific antibodies, as revealed in a recent study. These antibodies can bind to two distinct epitopes of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and have demonstrated the ability to neutralize various strains of the virus, including the Omicron variant.

14 Mar 2023

Monoclonal Antibody News and Research

Further Reading

Bioengineered drug candidate can counter S. aureus infection in early tests

Antibody combination strongly protects high-risk people with early COVID-19 symptoms, trial shows

The economic burden of RSV infections in low and middle-income countries

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

mAb therapy reduces risk of hospitalization and death against Alpha, Delta, and Omicron variants

Omicron BA.5 variant demonstrates increased neuroinvasiveness and pathogenicity in mice

Probiotic E. coli secretes proteins of therapeutic value into its surroundings

Lab-made antibodies may be able to cure people infected with yellow fever

New combination therapy shows promising results in some patients with advanced head and neck cancer

New study suggests broad neutralizing antibody could provide three years of COVID protection

Disruption of the FcRn–IgG interaction may make AAV-based gene therapies effective

H5N1 avian influenza found in stranded harbor porpoise

Does vitamin D play an anti-viral role against SARS-CoV-2?

Monoclonal antibody-based blocking ELISA for SARS-CoV-2 detection in animals

How to assess clinical response in multiple myeloma

Study suggests mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

New class of oral drugs can inhibit a diverse range of pathogenic SARS-CoV-2 strains

Nasal administration of a fully human anti-CD3 monoclonal antibody modulates T cell inflammatory responses in COVID-19

Pilot trial tests nasal monoclonal antibody treatment for COVID-19

Antibodies eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News